Abiraterone Acetate (Zytiga®) for mCRPC

Assessment Status NCPE Assessment Process Complete
Drug Abiraterone Acetate
Brand Zytiga®
Indication Treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) who have received prior docetaxel-based chemotherapy.
Assessment Process
Rapid review commissioned 21/10/2011
Rapid review completed 02/11/2011
Rapid review outcome Full Pharmacoeconomic Assessment Recommended
Full submission received from Applicant 12/12/2011
NCPE assessment completed 22/05/2012
NCPE assessment outcome Reimbursement not recommended at the submitted price

Technical Summary

May 2014

The HSE has approved reimbursement following confidential price negotiations.